Valuation: Tibet Duo Rui Pharmaceutical Co., Ltd.

Market Cap 5.01B 737M 644M 594M 550M 1.04B 70.31B 1.06B 7.12B 2.79B 34.53B 2.77B 2.71B 120B P/E 2024
-22.7x
P/E 2025 -46.3x
Enterprise Value 5.33B 785M 686M 633M 586M 1.11B 74.9B 1.13B 7.58B 2.97B 36.78B 2.95B 2.88B 127B EV / Sales 2024
6.46x
EV / Sales 2025 32.7x
Free-Float
30.57%
Yield 2024 *
-
Yield 2025 -
04-28 Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-23 Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
04-22 Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Hubei Hairuidi Pharmaceutical Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 2.4 million. CI
04-22 Tibet Jiakang TImes Technology Development Co., Ltd. entered into an Equity Transfer Agreement to acquire 69% stake in Xiamen Ruitilian Pharmaceutical Technology Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 27.6 million. CI
04-22 Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Wuhan Duorui Industrial Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 5.1 million. CI
02-26 Wang Qingtai and Cao Xiaobing completed the acquisition of an additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd. CI
02-24 Trading in Tibet Duo Rui Pharmaceutical's shares to halt RE
01-20 Wang Qingtai and Cao Xiaobing proposed to acquire additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 620 million. CI
12-04 Wang Qingtai, Cui Zihao and Cao Xiaobing completed the acquisition of 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd. CI
25-10-23 Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-10-12 Wang Qingtai, Cui Zihao and Cao Xiaobing signed an share transfer agreement to acquire 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 760 million. CI
25-09-29 Duorui Pharma Expects Control Change Amid Parents' Plan MT
25-09-28 Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2025. CI
1 day-2.28%
1 week-0.76%
Current month+2.88%
1 month-17.46%
3 months-7.35%
6 months+4.98%
Current year-1.71%
1 week 55.81
Extreme 55.81
64.66
1 month 54.89
Extreme 54.89
71.29
Current year 54.89
Extreme 54.89
98.29
1 year 30.51
Extreme 30.51
98.29
3 years 12.6
Extreme 12.6
98.29
5 years 12.6
Extreme 12.6
98.29
10 years 12.6
Extreme 12.6
98.29
Manager TitleAgeSince
Chief Executive Officer 60 2018-11-30
Director of Finance/CFO 47 2017-04-30
Director of Finance/CFO 46 2017-11-30
Director TitleAgeSince
Director/Board Member 48 2020-02-20
Chairman 60 2017-11-30
Director/Board Member 70 2020-02-20
Change 5-day change 1-year change 3-year change Capi.($)
-2.28%-0.76%+102.73%+140.47% 681M
+0.09%+0.25%+54.65%+169.19% 1,085B
-1.63%-1.50%+65.79%+62.70% 624B
-1.12%-4.27%+31.10%+84.44% 442B
+0.97%-0.59%+28.75%+27.65% 332B
-2.01%-9.46%+23.17%+28.57% 277B
+0.60%-2.22%+26.08%+45.81% 282B
+0.71%-1.53%-29.34%-39.37% 217B
-1.19%-2.81%+22.63%+66.30% 196B
-0.72%+2.72%+19.07%+81.19% 167B
Average -0.25%-1.73%+34.46%+66.69% 362.26B
Weighted average by Cap. +0.21%-1.06%+38.30%+85.07%

Financials

2024 2025
Net sales 241M 35.41M 30.98M 28.56M 26.43M 50.16M 3.38B 51M 342M 134M 1.66B 133M 130M 5.75B 154M 22.69M 19.85M 18.3M 16.93M 32.14M 2.17B 32.68M 219M 85.92M 1.06B 85.17M 83.33M 3.68B
Net income -62.67M -9.22M -8.07M -7.44M -6.88M -13.06M -880M -13.28M -89.09M -34.92M -432M -34.62M -33.87M -1.5B -102M -15.03M -13.15M -12.13M -11.22M -21.3M -1.44B -21.66M -145M -56.94M -705M -56.44M -55.22M -2.44B
Net Debt 135M 19.82M 17.34M 15.99M 14.79M 28.08M 1.89B 28.55M 191M 75.06M 929M 74.4M 72.79M 3.22B 327M 48.08M 42.06M 38.79M 35.89M 68.12M 4.59B 69.25M 464M 182M 2.25B 180M 177M 7.81B
Logo Tibet Duo Rui Pharmaceutical Co., Ltd.
Tibet Duo Rui Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical preparations, intermediates and active pharmaceutical ingredients. The Company mainly has self-produced products such as Sodium Acetate Ringer Injection and agent products such as Amoxicillin Sodium and Clavulanate Potassium for Injection. The Company's products mainly include liquid therapy, emergency medication, pediatric medication, psychiatric medication, and analgesic medication. The Company mainly operates its businesses in the domestic market.
Employees
461
Date Price Change Volume
26-07-09 CN¥58.65 -2.28% 2,049,284
26-07-08 CN¥60.02 -0.22% 1,549,700
26-07-07 CN¥60.15 +0.65% 1,468,900
26-07-06 CN¥59.76 +1.39% 2,100,725
26-07-03 CN¥58.94 -0.27% 1,094,601
  1. Stock Market
  2. Stocks
  3. 301075 Stock